Glutamatergic conception of mood disorders;Koncepcja glutaminergiczna chorób afektywnych

Psychiatria Polska

Volumn 45, Issue 6, 2011, Pages 875-888

  Permoda Osip, Agnieszka ^a   Rybakowski, Janusz ^a  

^a Poznan University of Medical Sciences   (Poland)

Author keywords

Bipolar mood disorder; Depression; Glutamatergic system

Indexed keywords

ANTIDEPRESSANT AGENT; GLUTAMATERGIC RECEPTOR; MOOD STABILIZER; NEUROTRANSMITTER RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM; DRUG MECHANISM; GENE; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GLUTAMATERGIC CONCEPTION; HUMAN; MOOD DISORDER; NEUROBIOLOGY; NEUROIMAGING; NEUROTRANSMISSION; PATHOGENESIS; UNIPOLAR AFFECTIVE DISORDER;

BRAIN; EXCITATORY AMINO ACID AGENTS; GLUTAMATES; GLUTAMIC ACID; HUMANS; MOOD DISORDERS; RECEPTORS, GLUTAMATE;

EID: 84055199106     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry 1965; 122: 509-522.
2. Lapin IP, Oxenkrug GF. Intensification of the central serotoninergic processes as a possibile determinant of the thymoleptic effect. Lancet 1969; 7586: 132-136.
3. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacol. 2008; 33: 88-109. (Pubitemid 350191319)
4. Maeng S, Zarate CA. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effect. Curr. Psychiatry Rep. 2007; 9: 467-474. (Pubitemid 350284937)
5. Paslakis G, Gass P, Deutschle M. Die Bedeutung des glutamatergen Systems für Pathophysiologie und Pharmakotherapie der Depression: präklinische und klinische Daten. Fortschr. Neurol. Psychiatr. 2010; 79: 1-9.
6. Ninan I, Bath KG, Dagar K, Perez-Castro R, Plummer MR, Lee FS i in. The BDNF Val66Met polymorphism impairs NMDA receptor-dependent synaptic plasticity in the hippocampus. J. Neurosc. 2010; 30: 8866-8870.
7. Kawashima H, Numakawa T, Kumamaru E, Adachi N, Mizuno H, Ninomiya M i in. Glucocrticoid attenuated brain-derived neurotrophic factor-dependent upregulation of glutamate receptors via the suppression of microRNA-132 expression. Neurosc. 2010; 165: 1301-1311.
8. Di Liberto V, Bonomo A, Frinchi M, Belluardo N, Mudo G. Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain. Neurosc. 2010; 165: 863-873.
9. Simonyi A, Christian MR, Sun AY, Sun GY. Chronic ethanol-induced subtype- and subregionspecific decrease in the mRNA expression of metabotropic glutamate receptors in rat hippocampus. Alcohol Clin. Exp. Res. 2004; 28: 1419-1423. (Pubitemid 39238302)
10. Stefansson H, Sigurdsson E, Steinhorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S i in. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 2002; 71: 877-892.
11. Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H i in. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc. Natl Acad. Sc. USA 2002; 99: 13675-13680. (Pubitemid 35215440)
12. Zhang Z, Li Y, Zhao Q, Huang K, Wang P, Yang P i in. First evidence of association between G72 and bipolar disorder in the Chinese Han population. Psychiatr. Gen. 2009; 19: 151-153.
13. Walker RM, Christoforou A, Thomson PA, McGhee KA, Maclean AM, Mühleisen TW. Association analysis of neuregulin 1 candidate regions in schizophrenia and bipolar disorder. Neurosc. Lett. 2010; 478: 9-13.
14. Mundo E, Tharmalingham S, Neves-Pereira M, Dalton EJ, Macciardi F, Parikh SV i in. Evidence that the N-methyl-D-aspartate subunit 1 receptor gene (GRIN1) confers susceptibility to bipolar disorder. Mol. Psychiatry 2003; 8: 241-245. (Pubitemid 36315234)
15. Martucci L, Wong AH, De Luca V, Likhodi O, Wong GW, King N i in. N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels. Schizophr. Res. 2006; 84: 214-221.
16. Szczepankiewicz A, Skibinska M, Rybakowski J, Leszczynska-Rodziewicz A, Tomaszewska M, Twarowska-Hauser J. Lack of association of three GRIN2B polymorphisms with bipolar disorder. World J. Biol. Psychiatry 2009;10: 469-473.
17. Szczepankiewicz A, Rybakowski JK, Skibińska M, Dmitrzak-Wȩglarz M, Leszczyńska-Rodziewicz A, Wilkoś ć M i in. FYN kinase gene: another glutamatergic gene associated with bipolar disorder? Neuropsychobiol. 2009; 59: 178-183.
18. Makino C, Fujii Y, Kikuta R, Hirata N, Tani A, Shibata A i in. Positive association of the AMPA receptor subunit GluR4 gene (GRIA4) haplotype with schizophrenia: linkage disequilibrium mapping using SNPs evenly distributed across the gene region. Am. J. Med. Genet B Neuropsychiatr. Genet 2003; 116 B: 17-22.
19. Shi J, Badner JA, Hattori E, Potash JB, Willour VL, McMahon FJ i in. Neurotransmission and bipolar disorder: a systematic familybased association study. Am. J. Med. Genet B Neuropsychiatr. Genet 2008; 147 B: 1270-1277.
20. Pickard BS, Malloy MP, Christoforou A, Thomson PA, Evans KL, Morris SW i in. Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder. Mol. Psychiatry 2006; 11: 847-857. (Pubitemid 44299106)
21. Pickard BS, Knight HM, Hamilton RS, Soares DC, Walker R, Boyd JK i in. A common variant in the 3'UTR of the GRIK4 glutamate receptor gene affects transcript abundance and protects against bipolar disorder. Proc. Natl Acad. Sc. USA 2008; 105: 14940-14945.
22. Schiffer HH, Heinemann SF. Association of the human kainate receptor GluR7 gene (GRIK3) with recurrent major depressive disorder. Am. J. Med. Genet B Neuropsychiatr. Genet 2007; 144 B: 20-26.
23. Fallin MD, Lasseter VK, Avramopoulos D, Nicodemus KK, Wolyniec PS, McGrath JA i in. Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am. J. Hum. Genet. 2005; 77: 918-936. (Pubitemid 41698514)
24. Dalvie S, Horn N, Nossek C, van der Merwe L, Stein DJ, Ramesar R. Psychosis and relapse in bipolar disorder are related to GRM3, DAOA, and GRIN2B genotype. Afr. J. Psychiatry 2010; 13: 297-301.
25. Bernard R, Kerman IA, Thompson RC, Jones EG, Bunney WE, Barchas JD i in. Altered expression of glutamate signalling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol. Psychiatry 2010, April 13 [e-pub ahead of print].
26. Zink M, Vollmayr B, Gebicke-Haerter PJ, Henn FA. Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression. Neuropharmacol. 2010; 58: 465-473.
27. Altamura CA, Mauri MC, Ferrara A, Moro AR, D'Andrea G, Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am. J. Psychiatry 1993; 150: 1731-1733. (Pubitemid 23325960)
28. Mitani H, Shirayama Y, Yamada T, Maeda K, Ashby CR Jr, Kawahara R. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Progr. Neuropsychopharmacol. Biol. Psychiatry 2006; 30: 1155-1158. (Pubitemid 43928219)
29. Levine J, Panchalingam K, Rapoport A, Gershon S, McClure RJ, Pettegrew JW. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol. Psychiatry 2000; 47: 586-593. (Pubitemid 30169251)
30. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol. Psychiatry 2007; 62: 1310-1316. (Pubitemid 350060893)
31. Yüksel C, Öngür D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol. Psychiatry 2010; 68: 785-794.
32. Nudmamud-Thanoi S, Reynolds GP. The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosc. Lett. 2004; 372: 173-177. (Pubitemid 39505251)
33. Boyce-Rustay JM, Holmes A. Genetic inactivation of the NMDA receptor NR2A subunit has anxiolyticand antidepressant-like effects in mice. Neuropsychopharmacol. 2006; 31: 2405-2414. (Pubitemid 44607058)
34. Scarr E, Pavey G, Sundram S, MacKinnon A, Dean B. Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder. Bipolar Disord. 2003; 5: 257-264. (Pubitemid 37009889)
35. Shaltiel G, Maeng S, Malkesman O, Pearson B, Schloesser RJ, Tragon T i in. Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol. Psychiatry 2008; 13: 858-872.
36. Feyissa AM, Woolverton WL, Miguel-Hidalgo JJ, Wang Z, Kyle PR, Hasler G i in. Elevated level of metabotropic glutamate receptor s/3 in the prefrontal cortex in major depression. Progr. Neuropharmacol. Biol. Psychiatry 2010; 34: 279-283.
37. Müller N, Schwarz MJ. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur. Arch. Psychiatry Clin. Neurosc. 2008; 258 (supl. 2): 977-106.
38. Myint AM, Kim YK, Verkerk R, Scharpe S, Steibusch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord. 2007; 98: 143-151. (Pubitemid 46048912)
39. Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 1996; 29: 23-26. (Pubitemid 26072654)
40. Nowak G, Legutko B, Solnick P, Popik P. Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors. Eur. J. Pharmacol. 1998; 342: 367-370. (Pubitemid 28149993)
41. Martinez-Turrillas R, DelRio J, Frechilla D. Neuronal proteins involved in synaptic targeting of AMPA receptors in rat hippocampus by antidepressant drugs. Biochem. Biophys. Res. Commun. 2007; 353: 750-755. (Pubitemid 46048734)
42. Nonaka S, Hough CJ, Chuang DM. Chronic lithium treatment robustly protects neurons in the central nervous system against neurotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc. Natl Acad. Sc. USA 1998; 95: 229-244.
43. Kopnisky KL, Chalecka-Franaszek E, Gonzalez-Zulueta M, Chuang DM. Chronic lithium treatment antagonizes glutamate-induced decrease of phosphorylated CREB in neurons via reducing protein phosphatase 1 and increasing MEK activities. Neurosc. 2003; 116: 425-435. (Pubitemid 36139913)
44. Shibuya-Tayoshi S, Tayoshi S, Sumitani S, Ueno S, Harada M, Ohmori T. Lithium effects on brain glutamatergic and GABAergic systems of healthy volunteers as measured by proton magnetic resonance spectroscopy. Progr. Neuropsychopharmacol. Biol. Psychiatry 2008; 32: 249-256.
45. Du J, Gray NA, Falke C, Yuan P, Szabo S, Manji HK. Structurally dissimilar antimanic agents modulate synaptic plasticity by regulating AMPA glutamate receptor subunit GluR1 synaptic expression. Ann NY Acad. Sc. 2003; 1003: 378-380. (Pubitemid 38083076)
46. Ahmad S, Fowler LJ, Whitton PS. Effects of combined lamotrigine and valproate on basal and stimulated extracellular amino acids and monoamines in the hippocampus of freely moving rats. Naunyn-Schmiederbergs Arch. Pharmacol. 2005; 371: 1-8. (Pubitemid 40379382)
47. Du J, Suzuki K, Wei Y, Wang Y, Blumenthal R, Chen Z i in. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacol. 2007; 32: 793-802. (Pubitemid 46426179)
48. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh MA i in. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant depression. Arch. Gen. Psychiatry 2006; 63: 856-864. (Pubitemid 44188478)
49. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S i in. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 2010; 67: 793-802.
50. Diazgranados N, Ibrahim L, Ameli R, Henter ID, Luckenbaugh DA, Machado-Vieira R i in. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J. Clin. Psychiatry 2010; 71: 1605-1611.
51. Salvadore G, Cornwell BR, Sambataro F, Latov D, Colon-Rosario V, Carver F i in. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacol. 2010; 35: 1415-1422.
52. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M i in. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329: 959-964.
53. Zarate CA, Payne JL, Quiroz J, Sporn J, Denikoff KK, Luckenbauch D i in. An open-label trial of riluzole in patients with treatment-resistant major depression. Am. J. Psychiatry 2004; 161: 171-174. (Pubitemid 38419327)
54. Zarate CA, Quiroz JA, Singh JB, Denikoff KD, de Jesus G, Luckenbauch D i in. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol. Psychiatry 2005; 57: 430-432. (Pubitemid 40215774)
55. Brennan BP, Hudson JI, Jensen JE, McCarthy J, Roberts JL, Prescot AP i in. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacol. 2010; 35: 835-846.
56. Papp M, Moryl E. Antidepressant-like effects of 1- aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression. Eur. J. Pharmacol. 1996; 316: 145-151. (Pubitemid 27008144)
57. Heresco-Levy U, Javitt DC, Gelfin Y, Gorelik E, Bar M, Blanaru M i in. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J. Affect. Disord. 2006; 93: 239-243. (Pubitemid 43816064)
58. Rogóż Z, Skuza G, Daniel WA, Wójcikowski J, Dudek D, Wróbel A. Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. Pharmacol. Rep. 2007; 59: 778-784. (Pubitemid 351586572)
59. Teng CT, Demetrio FN. Memantine may acutely improve cognition and have a mood-stabilizing effect in treatment-resistant bipolar disorder. Rev. Bras. Psiquiatr. 2006; 28: 252-254.
60. Zarate CA Jr, Singh JB, Quiroz JA, de Jesus G, Denicoff KK, Luckenbaugh DA i in. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am. J. Psychiatry 2006; 163: 153-155. (Pubitemid 43050119)
61. Mony L, Kew JN, Gunthorpe MJ, Paoletti P. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Brit. J. Pharmacol. 2009; 157: 1301-1317.
62. Szewczyk B, Poleszak E, Sowa-Kućma M, Wróbel A, Słotwiński S, Listos J i in. The involvement of NMDA and AMPA receptors in the mechanism of antidepressant-like action of zinc in the forced swim test. Amino Acids 2010; 39: 205-217.
63. Siwek M, Dudek D, Paul IA, Sowa-Kućma M, Ziȩba A, Popik P i in. Zinc supplementation augments efficacy of imipramine in treatment-resistant patients: a double-blind, placebo-controlled study. J. Affect. Disord. 2009; 118: 187-195.
64. Poleszak E, Wlaź P, Kȩdzierska E, Radziwoń-Zaleska M, Pilc A, Fidecka S i in. Effect of acute and chronic treatment with magnesium in the forced swim test in rats. Pharmacol. Rep. 2005; 57: 654-658.
65. Eby GA, Eby KL. Magnesium for treatment-resistant depression: a review and hypothesis. Med. Hypoth. 2010; 74: 649-660.